<DOC>
	<DOCNO>NCT00334672</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth hemophagocytic lymphohistiocytosis cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill hemophagocytic lymphohistiocytosis cell . A donor stem cell transplant may able replace blood-forming cell destroy chemotherapy . Sometimes transplanted cell donor make immune response body 's normal cell . Cyclosporine methotrexate may stop happen . PURPOSE : This phase III trial study well combination chemotherapy follow donor stem cell transplant work treat patient hemophagocytic lymphohistiocytosis .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Donor Stem Cell Transplant Treating Patients With Hemophagocytic Lymphohistiocytosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Provide evaluate revise induction maintenance therapy comprise etoposide , dexamethasone , cyclosporine , term achieve maintain acceptable clinical condition order perform curative allogeneic hematopoietic stem cell transplantation ( AHSCT ) , patient primary inherit severe persistent secondary hemophagocytic lymphohistiocytosis ( HLH ) . - Evaluate improve outcome AHSCT various type donor . - Determine prognostic importance state remission time AHSCT . - Evaluate neurological complication , term early neurological alteration cerebrospinal fluid ( CSF ) finding , patient treat regimen . Secondary - Improve understand pathophysiology HLH conduct biological study genetics cytotoxicity patient , include genotype-phenotype study prognostic value natural killer ( NK ) cell activity subtyping . OUTLINE : This multicenter study . - Induction therapy ( week 1-8 ) : Patients receive etoposide IV 1-3 hour twice weekly week 1 2 weekly week 3-8 . Patients also receive dexamethasone IV orally daily cyclosporine IV orally twice daily week 1-8 . Patients clinically evident , progressive neurological symptom abnormal cerebrospinal fluid ( CSF ) ( cell count protein ) improve 2 week induction therapy undergo intrathecal therapy comprise methotrexate hydrocortisone weekly week 3-6 . Patients evaluate 8 week induction therapy . Patients primary ( i.e. , familial ) hemophagocytic lymphohistiocytosis ( HLH ) genetic evidence HLH proceed maintenance therapy . Patients severe persistent secondary ( i.e. , nonfamilial ) HLH genetic evidence HLH proceed maintenance therapy disease still active induction therapy . Patients nonfamilial HLH genetic evidence HLH achieve complete remission ( CR ) discontinue treatment . If disease reactivates , may proceed allogeneic hematopoietic stem cell transplantation ( AHSCT ) . - Maintenance therapy ( week 9-40 ) : Patients receive dexamethasone IV day 1-3 week 10 , 12 , 14 , 16 , 18 , 20 , 22 , 24 , 26 , 28 , 30 , 32 , 34 , 36 , 38 , 40 ; etoposide IV 1-3 hour week 9 , 11 , 13 , 15 , 17 , 19 , 21 , 23 , 25 , 27 , 29 , 31 , 33 , 35 , 37 , 39 ; cyclosporine IV orally twice daily week 9-40 . After completion maintenance therapy , patient primary ( i.e. , familial ) HLH , severe persistent secondary ( i.e. , nonfamilial ) HLH , reactivate disease proceed AHSCT . Patients nonfamilial HLH complete maintenance therapy , go receive AHSCT , may recommend additional maintenance therapy discretion treat physician . - AHSCT : - Preparative regimen : Patients receive preparative regimen comprise busulfan orally IV four time daily day -8 -5 , etoposide IV 6 hour day -4 , cyclophosphamide IV 1 hour day -3 -2 . Patients undergo unrelated AHSCT , also receive antithymocyte globulin ( ATG ) IV 12 hour day -3 -1 . - Transplantation : Patients undergo AHSCT day 0 . - Graft-versus-host disease prophylaxis : Beginning day -1 , patient receive cyclosporine IV continuously orally , tolerate , daily 6-12 month . Patients also receive methotrexate* IV day 1 , 3 , 6 . NOTE : *As substitute methotrexate , patient may receive oral mycophenolate mofetil twice daily day 0-40 , follow taper discontinuation . Patients undergo periodic blood collection bone marrow biopsy biological study . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 288 patient accrue study .</detailed_description>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose hemophagocytic lymphohistiocytosis ( HLH ) meet 1 follow criteria* : Diagnosis molecular/genetic method Diagnosis meeting 5 8 follow criterion : Clinical criterion : Fever Splenomegaly Laboratory criterion : Cytopenias affect ≥ 2 3 lineage peripheral blood , include follow : Hemoglobin &lt; 9.0 g/dL ( &lt; 10.0 g/dL infant &lt; 4 week age ) Platelet count &lt; 100,000/mm^3 Neutrophil count &lt; 1,000/mm^3 Hypertriglyceridemia and/or hypofibrinogenemia : Fasting triglyceride ≥ 3.0 mmol/L ( i.e. , ≥ 265 mg/dL ) Fibrinogen ≤ 1.5 g/L Histopathologic criterion : Hemophagocytosis bone marrow , spleen , lymph node No evidence malignancy New diagnostic criterion : Low absent natural killer ( NK ) cell activity Ferritin ≥ 500 mcg/L Soluble CD25 ( i.e. , soluble interleukin2 receptor ) ≥ 2,400 U/mL NOTE : *Patients meet diagnostic criterion HLH strong clinical suspicion HLH may eligible discretion investigator Primary HLH ( i.e. , familial hemophagocytic lymphohistiocytosis [ FLH ] ) OR secondary HLH ( i.e. , severe acquire form HLH ) Acceptable donor meeting 1 follow criterion : HLAidentical relate donor Matched unrelated donor Mismatched unrelated donor Familial haploidentical donor PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : No prior cytotoxic treatment HLH No prior cyclosporine treatment HLH</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>hemophagocytic lymphohistiocytosis</keyword>
</DOC>